Incyte Co. (NASDAQ:INCY) – SunTrust Banks boosted their Q2 2018 EPS estimates for shares of Incyte in a report issued on Thursday. SunTrust Banks analyst P. Lawson now anticipates that the biopharmaceutical company will post earnings per share of $0.05 for the quarter, up from their previous forecast of $0.04. SunTrust Banks also issued estimates for Incyte’s FY2020 earnings at $3.56 EPS, FY2021 earnings at $5.72 EPS and FY2022 earnings at $7.88 EPS.

A number of other equities analysts have also recently issued reports on INCY. BidaskClub raised Incyte from a “strong sell” rating to a “sell” rating in a report on Friday. Oppenheimer reaffirmed a “hold” rating and issued a $110.00 target price (down previously from $120.00) on shares of Incyte in a report on Monday, January 22nd. BMO Capital Markets reaffirmed a “buy” rating and issued a $172.00 target price on shares of Incyte in a report on Wednesday, January 3rd. Goldman Sachs Group began coverage on Incyte in a research report on Friday, October 6th. They issued a “buy” rating and a $160.00 price target on the stock. Finally, Jefferies Group reiterated a “buy” rating on shares of Incyte in a research report on Friday, October 6th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $143.25.

Incyte (NASDAQ:INCY) opened at $95.51 on Friday. Incyte has a fifty-two week low of $88.81 and a fifty-two week high of $153.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. The stock has a market capitalization of $20,420.00, a PE ratio of -119.39 and a beta of 0.74.

Incyte (NASDAQ:INCY) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.11. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The business had revenue of $381.50 million during the quarter, compared to analysts’ expectations of $360.34 million. During the same quarter in the prior year, the firm earned $0.19 EPS. The business’s revenue for the quarter was up 41.6% compared to the same quarter last year.

Large investors have recently made changes to their positions in the business. Inverness Counsel LLC NY bought a new position in Incyte in the third quarter worth approximately $330,000. LMR Partners LLP bought a new position in Incyte in the third quarter worth approximately $394,000. Swiss National Bank boosted its holdings in Incyte by 3.0% in the third quarter. Swiss National Bank now owns 641,700 shares of the biopharmaceutical company’s stock worth $74,912,000 after acquiring an additional 18,700 shares in the last quarter. Matrix Capital Management Company LP boosted its holdings in Incyte by 28.3% in the second quarter. Matrix Capital Management Company LP now owns 1,796,716 shares of the biopharmaceutical company’s stock worth $226,225,000 after acquiring an additional 396,716 shares in the last quarter. Finally, Prudential Financial Inc. boosted its holdings in Incyte by 0.6% in the third quarter. Prudential Financial Inc. now owns 236,699 shares of the biopharmaceutical company’s stock worth $27,633,000 after acquiring an additional 1,490 shares in the last quarter. Institutional investors and hedge funds own 90.75% of the company’s stock.

In related news, insider David W. Gryska sold 3,915 shares of the company’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total transaction of $413,541.45. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Paul A. Friedman sold 28,507 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $105.24, for a total value of $3,000,076.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 44,878 shares of company stock worth $4,636,494. 17.70% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Q2 2018 EPS Estimates for Incyte Co. (INCY) Increased by Analyst” was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.watchlistnews.com/q2-2018-eps-estimates-for-incyte-co-incy-increased-by-analyst/1828656.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.